Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Повышение приверженности лечению пациентов с болевыми синдромами: выбор нестероидного противовоспалительного препарата
Повышение приверженности лечению пациентов с болевыми синдромами: выбор нестероидного противовоспалительного препарата
Ал.Б.Данилов, О.Р.Добрушина. Повышение приверженности лечению пациентов с болевыми синдромами: выбор нестероидного противовоспалительного препарата. Consilium Medicum. Неврология (Прил.). 2011; 1: 29-34.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Weberschock TB, Muller S-M, Boehncke S, Boehncke W-H. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res 2007; 299: 169–75.
2. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998; 53: 1231–3.
3. Харкевич Д.А. Фармакология. М.: ГЭОТАР-МЕД, 1999.
4. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276–9.
5. Abramson S. Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1991; 3: 336–40.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.
7. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002; 62: 2637–51; discussion 2652–351; discussion 2652–3.
8. Agrawal NGB, Porras AG, Matthews CZ et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003; 43: 268–76.
9. Kassahun K, McIntosh IS, Shou M et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001; 29: 813–20.
10. Hunt RH, Harper S, Callegari P et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003; 17: 201–10.
11. Hunt RH, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725–33.
12. Baraf HS, Fuentealba C, Greenwald M et al. Tolerability and effectiveness of etoricoxib compared to diclofenacsodium in patients with osteoarthritis: a randomized controlledstudy (EDGE trial). Arthitis Rheum 2004; 50: 832.
13. Curtis SP, Ng J, Yu Q et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004; 26: 70–83.
14. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068–73.
15. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009; 48: 425–32.
16. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
17. Chan CC, Reid CM, Aw T-J et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332–41.
18. Etoricoxib Protocol 042 Study Group. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain 2003; 4: 307–15.
19. Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; CD004309.
20. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Safety of etoricoxib in patients with reactions to NSAIDs. J Investig Allergol Clin Immunol 2008; 18: 163–7.
21. Scholes D, Stergachis A, Penna PM et al. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995; 22: 708–12.
22. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27: 1020–7.
23. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther 2008; 10: R53.
2. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998; 53: 1231–3.
3. Харкевич Д.А. Фармакология. М.: ГЭОТАР-МЕД, 1999.
4. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276–9.
5. Abramson S. Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1991; 3: 336–40.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.
7. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002; 62: 2637–51; discussion 2652–351; discussion 2652–3.
8. Agrawal NGB, Porras AG, Matthews CZ et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003; 43: 268–76.
9. Kassahun K, McIntosh IS, Shou M et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001; 29: 813–20.
10. Hunt RH, Harper S, Callegari P et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003; 17: 201–10.
11. Hunt RH, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725–33.
12. Baraf HS, Fuentealba C, Greenwald M et al. Tolerability and effectiveness of etoricoxib compared to diclofenacsodium in patients with osteoarthritis: a randomized controlledstudy (EDGE trial). Arthitis Rheum 2004; 50: 832.
13. Curtis SP, Ng J, Yu Q et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004; 26: 70–83.
14. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068–73.
15. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009; 48: 425–32.
16. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
17. Chan CC, Reid CM, Aw T-J et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332–41.
18. Etoricoxib Protocol 042 Study Group. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain 2003; 4: 307–15.
19. Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; CD004309.
20. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Safety of etoricoxib in patients with reactions to NSAIDs. J Investig Allergol Clin Immunol 2008; 18: 163–7.
21. Scholes D, Stergachis A, Penna PM et al. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995; 22: 708–12.
22. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27: 1020–7.
23. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther 2008; 10: R53.
Авторы
Ал.Б.Данилов, О.Р.Добрушина
Кафедра нервных болезней ФППОВ Первого МГМУ им. И.М.Сеченова
Кафедра нервных болезней ФППОВ Первого МГМУ им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.